NANO Nanobiotix SA

NANOBIOTIX Voting Rights and Shares Capital of the Company

NANOBIOTIX Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Nov. 08, 2022 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website:

Date

Number of Shares

Outstanding

Total number of voting rights
Total voting rights,

theoretical(1)

Total voting rights,

exercisable(2)
October 31, 2022

34,875,87236,286,31336,273,212

(1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at or follow us on and . 

Contacts

Nanobiotix



Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835







Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388





Media Relations



France –Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51





LifeSci Advisors

Ligia Vela-Reid

+44 (0) 7413825310





EN
08/11/2022

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 10 juin 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 mai 202547 426 85149 529 24449 507 126 À prop...

June 10, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 10, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2May 31, 202547,426,85149,529,24449,507,126   About NANOBIOTIX...

June 10, 2025 1 EN
Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 10,780 shares at 3.415EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

05/28/25 May 28, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ...

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, NYPresenter...

May 28, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX participera à la conférence investisseurs annuelle Jefferie...

NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global Healthcare PARIS et CAMBRIDGE, Mass., 28 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : Conférence Jefferies Global HealthcareDate : jeu...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch